NCT07172646View on ClinicalTrials.gov

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

April 30, 2027

Conditions

Hyperlipoproteinemia (a)

Interventions

DRUG

SRSD216 injection

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

100000

RECRUITING

Site 01, Beijing

All Listed Sponsors

lead

Sirius Therapeutics Co., Ltd.

INDUSTRY